A team of researchers from Charité – Universitätsmedizin Berlin and the Deutsches Rheuma-Forschungszentrum (DRFZ) Berlin, a Leibniz Institute, have successfully treated two patients with the autoimmune disease systemic lupus erythematosus. Using daratumumab, a monoclonal antibody which targets specific immune cells known as plasma cells, the researchers were able to modulate the abnormal immunological memory processes found in these patients. Treatment induced sustainable clinical responses and resulted in a reduction in systemic inflammation.
- CCS can rapidly reduce emissions in sectors that have few other options to decarbonize, EFI/Stanford
- Robotic trunk support trainer improves upper body control of children with cerebral palsy
- COVID-19 infection may be part of a ‘perfect storm’ for Parkinson’s disease
- NRL researchers evaluate ultraviolet sources, combat COVID-19
- AI detects hidden earthquakes